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Abstract
The aim of this study was to compare CLSI and EUCAST MIC and disk diffusion carbapenem breakpoints for the detection of carbapenem-
ase-producing Klebsiella pneumoniae. K. pneumoniae strains with known KPC (n = 31) or VIM (n = 20) carbapenemases were characterized
by disk diffusion (Oxoid) and Etest (bioMe´rieux) vs. imipenem, meropenem and ertapenem, and with VITEK2 (bioMe´rieux, five different
cards). Extended-spectrum b-lactamase (ESBL) testing was performed with VITEK2 (bioMe´rieux), ESBL combination disks (Becton
Dickinson) and the ESBL Etest (bioMe´rieux). With CLSI and EUCAST MIC breakpoints, respectively, 11 and seven of the strains were
susceptible to imipenem, 12 and eight to meropenem, and seven and none to ertapenem. The EUCAST epidemiological cut-off (ECOFF)
values for meropenem and ertapenem identified all carbapenemase producers, whereas the imipenem ECOFF failed in five strains. All
carbapenemase producers were detected with EUCAST disk diffusion breakpoints for ertapenem and meropenem, and four strains were
susceptible to imipenem. CLSI disk diffusion breakpoints characterized 18 (imipenem), 14 (meropenem) and three (ertapenem) isolates as
susceptible. When cards with a single carbapenem were used, detection failures with VITEK2 were four for imipenem, none for merope-
nem and one for ertapenem. Cards containing all three carbapenems had one to two failures. With ESBL combination disks, 21/31 KPC
producers and 2/20 VIM producers were positive. With VITEK2, no VIM producers and between none and seven KPC producers were
ESBL-positive. All carbapenemase producers were detected with the meropenem MIC ECOFF, or the clinical EUCAST breakpoint for
ertapenem. EUCAST disk diffusion breakpoints for meropenem and ertapenem detected all carbapenemase producers. VITEK2 had
between none and four failures in detecting carbapenemase producers, depending on the antibiotic card.
Keywords: AmpC, KPC, metallo-b-lactamase, porin, VIM
Original Submission: 30 March 2010; Revised Submission: 28 May 2010; Accepted: 29 May 2010
Editor: R. Canto´n
Article published online: 23 July 2010
Clin Microbiol Infect 2011; 17: 668–674
10.1111/j.1469-0691.2010.03299.x
Corresponding author: M. Vading, Department of Infectious Dis-
eases I73, Karolinska University Hospital, Hudddinge, SE-14186 Stock-
holm, Sweden
E-mail: malin.vading@karolinska.se
Introduction
In recent years, carbapenem resistance resulting from
b-lactamase production among Enterobacteriaceae (especially
Klebsiella pneumoniae) has increased [1]. KPC is the most
common class A carbapenemase and VIM is the most com-
mon class B b-lactamase among K. pneumoniae strains. Both
enzymes effectively inactivate most b-lactam antibiotics,
including carbapenems, restricting treatment options [2].
Recently, it has been proposed that carbapenemases of all
molecular classes should be designated as extended-spec-
trum b-lactamases (ESBLs)CARBA [3].
In some countries, carbapenemase-producing Enterobacteri-
aceae have become a public health problem. In Greece, an
increase in imipenem-resistant K. pneumoniae from 1% in
2001 to 20–50% (hospital wards/intensive-care units) in 2006
was observed [4]. Other countries, such as Israel and the
USA, have experienced similar problems [1,5–7]. Whereas
Israel and the USA have experienced mainly a problem with
KPC-producing K. pneumoniae, the carbapenemase-producing
strains in Greece have included both VIM and KPC producers
[4,8], and, lately, also strains with the simultaneous presence
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of VIM and KPC enzymes [9]. This results in a multidisciplin-
ary challenge spanning diagnostic microbiology, infection
control and antimicrobial treatment [10,11]. Few antimicro-
bial alternatives exist, and infections with carbapenemase-
producing K. pneumoniae are associated with a high mortality
rate [5,7,12]. The MICs of carbapenemase-producing strains
differ between strains, and some strains have MICs for carba-
penems below the current clinical susceptibility breakpoints
[1,11]. The current clinical breakpoints used in Europe and
the USA are, at present, not set to detect all carbapenamase-
producing Enterobacteriaceae.
The aim of this study was to compare the performance of
disk diffusion, MIC testing with Etest and VITEK2 in detect-
ing carbapenemase (KPC or VIM)-producing K. pneumoniae,
using the CLSI and EUCAST breakpoint systems. Further-
more, the performance of ESBL tests among carbapenemase
producers was examined with ESBL combination disk testing
(CDT), ESBL Etest and VITEK2. The results were inter-
preted with both CLSI and EUCAST breakpoints, as well as
EUCAST epidemiological cut-off (ECOFF) values.
Materials and Methods
Selection of strains
A total of 51 isolates of carbapenem-non-susceptible K. pneu-
moniae with known KPC production (n = 31) or VIM pro-
duction (n = 20) were tested. The clinical isolates were
collected from microbiological laboratories in Sweden,
Greece, the USA and Norway, and had earlier been genotyp-
ically characterized [13–15]. Previously conducted epidemio-
logical typing had shown that the majority of the KPC
producers belonged to sequence type 258, but a certain level
of diversity was observed within this clone [14]. Among the
VIM producers, the diversity was greater [13].
Disk diffusion susceptibility testing
Antibiotic susceptibility testing was performed by the disk dif-
fusion method, with Mueller–Hinton II agar (Becton Dickinson,
Franklin Lakes, NJ, USA), according to EUCAST (http://
www.eucast.org/eucast_disk_diffusion_test/disk_diffusion_method
ology/; last accessed 25 March 2010) and CLSI methodology
[16]. The plates were inoculated with samples of each strain
adjusted to a turbidity of 0.5 McFarland. Disks containing
10 lg of imipenem, meropenem or ertapenem (Oxoid, Bas-
ingstoke, UK) were applied to the surface of the inoculated
agar, and the plates were incubated for 20 h at 35C. The
strains were interpreted according to current CLSI and EU-
CAST breakpoints. The CLSI breakpoints for susceptibility
are ‡16 mm for imipenem, ‡16 mm for meropenem and
‡19 mm for ertapenem [16]. The EUCAST disk diffusion
breakpoints for susceptibility are ‡21 mm for imipenem,
‡22 mm for meropenem and ‡25 mm for ertapenem (http://
www.eucast.org/clinical_breakpoints; last accessed 25 May
2010). Furthermore, ECOFFs, the lower borders of the wild-
type populations, were applied. The carbapenem ECOFFs for
K. pneumoniae are 23 mm for imipenem, 24 mm for merope-
nem and 25 mm for ertapenem (G. Kahlmeter, personal
communication).
Etest
The MICs for imipenem, meropenem and ertapenem were
determined with Etest (bioMe´rieux, Marcy l’Etoile, France)
carried out on Mueller–Hinton II agar (Becton Dickinson),
according to the manufacturer’s instructions, and interpreted
according to clinical breakpoints from the CLSI and
EUCAST. The CLSI breakpoints are £4 mg/L for imipenem-
susceptible, ‡16 mg/L for imipenem-resistant, £4 mg/L for
meropenem-susceptible, ‡16 mg/L for meropenem-resistant,
£2 mg/L for ertapenem-susceptible, and ‡8 mg/L for ertape-
nem-resistant [16]. The EUCAST clinical breakpoints are
£2 mg/L for imipenem-susceptible, >8 mg/L for imipenem-
resistant, £2 mg/L for meropenem-susceptible, >8 mg/L for
meropenem-resistant, £0.5 mg/L for ertapenem-susceptible
and >1 mg/L for ertapenem-resistant (http://www.eucast.org/
clinical_breakpoints; last accessed 25 March 2010). The
strains were also analysed according to carbapenem ECOFFs,
which, in K. pneumoniae, are £1mg/L for imipenem,
£0.125 mg/L for meropenem and £0.064 mg/L for ertapenem
(http://www.eucast.org/mic_distributions/; last accessed 25
March 2010).
VITEK2
Colonies from an overnight agar plate culture of each isolate
were suspended in 3 mL of 0.45% saline and adjusted to a
turbidity of 0.5–0.63 McFarland standard with VITEK Densi-
check (bioMe´rieux). Antimicrobial susceptibility testing of the
isolates was performed with VITEK2 (bioMe´rieux), using five
different cards containing imipenem, meropenem or ertape-
nem, and combinations of these: AST N025 (imipenem,
meropenem and ertapenem), AST N027 (imipenem),
AST N029 (meropenem), AST N106 (ertapenem) and
AST N107 (imipenem, meropenem and ertapenem). In the
VITEK2 report, the MIC correlates are reported and the
advanced expert system interprets the results. For all cards
except AST N029, an ESBL test was included in the card.
ESBL CDT
ESBL CDT was performed with commercial disks (Becton
Dickinson), according to the manufacturer’s instructions,
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using Mueller–Hinton II agar (Becton Dickinson) and an inoc-
ulation turbidity of 0.5 McFarland. The disks used were cefo-
taxime 30 lg and cefotaxime/clavulanic acid 30/10 lg, as well
as ceftazidime 30 lg and ceftazidime/clavulanic acid 30/10 lg.
The results were interpreted according to the manufac-
turer’s instruction, where a zone increment of ‡5 mm fol-
lowing addition of clavulanic acid is considered to be a
positive test result.
ESBL Etest
The ESBL Etest (bioMerieux, Marcy I’Etoile, France) was
performed with three different antibiotic combinations: cefo-
taxime/cefotaxime + clavulanic acid, ceftazidime/ceftazidime +
clavulanic acid and cefepime/cefepime + clavulanic acid. The
test was performed and interpreted according to the manu-
facturer’s instructions.
Results
Disk diffusion and Etest
According to the CLSI disk diffusion breakpoints, 18 isolates
were susceptible to imipenem, 14 to meropenem and three
to ertapenem (Tables 1 and 2; Fig. 1). In contrast, when
EUCAST disk diffusion breakpoints were used, four isolates
were categorized as susceptible to imipenem, and none to
meropenem and ertapenem. All strains had inhibition zone
diameters below the ECOFFs for all carbapenems. The
observed maximum zone diameters for all KPC producers
were 21 mm for imipenem, 20 mm for meropenem and
17 mm for ertapenem, and for the VIM producers they were
21 mm for all three carbapenems.
With the Etest, based on the MIC breakpoints from the
CLSI and EUCAST, respectively, 11 and seven strains were
susceptible to imipenem, 12 and eight to meropenem, and
seven and none to ertapenem (Tables 1 and 2; Fig. 2). For
meropenem and ertapenem, all strains had MICs exceeding
the ECOFF. Five strains had MICs below the imipenem
ECOFF, all of them KPC producers.
VITEK2
No failures were observed with the use of AST N029 (con-
taining meropenem only). All strains were interpreted by the
expert system as carbapenemase-producing (Tables 1 and 2).
With AST N025 (imipenem, meropenem and ertapenem),
AST N027 (imipenem), AST N106 (ertapenem) and
TABLE 1. MIC (Etest), disk diffusion zone diameters and VITEK2 results for KPC-producing Klebsiella pneumoniae
Isolate
MIC (mg/L)
Zone
diameters (mm)
VITEK2 MIC correlates (mg/L) and advanced expert system interpretation with various cards
N25 N27 N29 N106 N107
IPM MEM ERT IPM MEM ERT IPM MEM ERT Carb IPM Carb MEM Carb ERT Carb IPM MEM ERT Carb
1534 16 >32 >32 14 13 12 ‡16 2 ‡8 Yes ‡16 Yes 4 Yes ‡8 Yes ‡16 2 ‡8 Yes
13663 8 >32 >32 13 6 8 8 ‡16 ‡8 Yes 4 Yes ‡16 Yes ‡8 Yes 4 ‡16 ‡8 Yes
14358 8 16 >32 21 16 9 8 8 ‡8 Yes 4 Yes 8 Yes ‡8 Yes 8 8 ‡8 Yes
14474 >32 8 4 19 20 17 4 1 4 Yes £1 No 1 Yes 4 Yes £1 4 4 Yes
70165 8 >32 >32 14 11 10 8 8 ‡8 Yes 8 Yes 8 Yes ‡8 Yes 4 4 ‡8 Yes
70261 >32 >32 >32 10 6 6 ‡16 ‡16 ‡8 Yes ‡16 Yes ‡16 Yes ‡8 Yes ‡16 ‡16 ‡8 Yes
70708 1 1 8 18 17 15 2 1 ‡8 Yes £1 No 2 Yes ‡8 Yes £1 1 4 Yes
71076 16 8 >32 20 14 12 4 4 ‡8 Yes ‡4 Yes 4 Yes ‡8 Yes £1 4 ‡8 Yes
71229 >32 16 >32 10 12 10 8 ‡16 ‡8 Yes 8 Yes 8 Yes ‡8 Yes ‡16 ‡16 ‡8 Yes
80050 32 2 8 20 18 13 4 1 ‡8 Yes 4 Yes 2 Yes ‡8 Yes 4 1 ‡8 Yes
2008022 32 8 >32 17 17 13 2 1 ‡8 Yes 2 Yes 1 Yes ‡8 Yes 2 1 4 Yes
2008023 2 4 >32 19 16 10 4 1 ‡8 Yes 2 Yes 2 Yes ‡8 Yes 4 1 ‡8 Yes
2008024 >32 >32 >32 6 6 6 ‡16 ‡16 ‡8 Yes ‡16 Yes ‡16 Yes ‡8 Yes ‡16 ‡16 ‡8 Yes
2008025 >32 >32 >32 13 13 8 ‡16 8 ‡8 Yes ‡16 Yes 8 Yes ‡8 Yes ‡16 8 ‡8 Yes
2008026 >32 >32 >32 6 6 6 4 2 ‡8 Yes 4 Yes 2 Yes ‡8 Yes 4 2 ‡8 Yes
2008027 >32 >32 >32 6 6 6 ‡16 ‡16 ‡8 Yes ‡16 Yes ‡16 Yes ‡8 Yes ‡16 ‡16 ‡8 Yes
2008028 0.5 1 2 21 20 14 4 1 ‡8 Yes £1 No 1 Yes 4 Yes £1 1 4 No
2008029 1 2 8 20 6 11 4 1 4 Yes £1 No 2 Yes ‡8 Yes 8 2 ‡8 Yes
2008030 >32 >32 2 18 17 17 2 1 ‡8 Yes 2 Yes 2 Yes ‡8 Yes 4 1 ‡8 Yes
2008031 4 >32 >32 15 13 10 8 8 ‡8 Yes 8 Yes ‡16 Yes ‡8 Yes 4 ‡16 ‡8 Yes
2008032 32 8 4 16 15 16 ‡16 4 4 Yes 8 Yes 4 Yes 4 Yes ‡16 4 4 Yes
K47-25 1 2 16 19 16 13 8 8 ‡8 Yes 8 Yes ‡16 Yes ‡8 Yes 4 ‡16 ‡8 Yes
K48-58 32 16 >32 11 14 7 8 ‡16 ‡8 Yes 4 Yes ‡16 Yes ‡8 Yes 8 ‡16 ‡8 Yes
K52-10 2 32 >32 18 13 6 4 ‡16 ‡8 Yes 2 Yes 2 Yes ‡8 Yes 4 ‡16 ‡8 Yes
K52-36 >32 >32 >32 12 6 9 8 ‡16 ‡8 Yes 4 Yes ‡16 Yes ‡8 Yes 4 ‡16 ‡8 Yes
K52-37 1 4 4 18 16 13 8 2 ‡8 Yes 4 Yes 2 Yes ‡8 Yes 4 1 ‡8 Yes
K52-43 4 2 8 19 11 10 4 2 ‡8 Yes 4 Yes 2 Yes ‡8 Yes 4 ‡16 ‡8 Yes
K52-74 >32 32 >32 14 13 10 4 ‡16 ‡8 Yes 4 Yes 4 Yes ‡8 Yes 8 8 ‡8 Yes
K53-64 4 4 8 15 11 8 4 1 ‡8 Yes 2 Yes ‡16 Yes ‡8 Yes 4 2 ‡8 Yes
K54-04 >32 >32 >32 8 7 6 4 8 ‡8 Yes 8 Yes ‡16 Yes ‡8 Yes ‡16 ‡16 ‡8 Yes
K54-05 >32 >32 >32 6 6 6 ‡16 ‡16 ‡8 Yes 8 Yes ‡16 Yes ‡8 Yes ‡16 ‡16 ‡8 Yes
IPM, imipenem; MEM, meropenem; ERT, ertapenem; Carb, interpreted as a carbapenamase producer by the advanced expert system.
Bold face denotes erroneous interpretation by the VITEK2 advanced expert system.
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AST N107 (imipenem, meropenem and ertapenem), respec-
tively, two, four, one and one failure was observed, where
the expert system interpreted the strain as ‘acquired cepha-
losporinase’ and, in one case with AST N027, ‘ESBL’ instead
of carbapenemase. The failure in AST N107 was interpreted
as ‘ESBL + impermeability (cephamycins)’.
ESBL Etest, disk diffusion and VITEK2
With ESBL Etests, none of the strains was ESBL-positive.
With the combination disks containing cefotaxime/cefotax-
ime + clavulanic acid, four KPC producers and none of the
VIM producers were ESBL-positive, whereas with the combi-
nation disks containing ceftazidime/ceftazidime + clavulanic
acid, 21 KPC producers and two VIM producers were
ESBL-positive. All VITEK2 antibiotic cards except AST N029
contained an ESBL test. With AST N025, no ESBL test was
positive, whereas the results with the other cards were,
respectively, one (AST N027), eight (AST N106) and six
(AST N107) positive ESBL reactions. One ESBL-positive
strain was a VIM producer (AST N106), and the rest were
KPC producers.
Discussion
Detection of carbapenemase-producing K. pneumoniae is
challenging from a laboratory point of view. Only the CLSI
has issued official recommendations for the detection of
carbapenemases, based on an MIC cut-off of 2 mg/L for all
carbapenems or zone diameters <22 mm [16]. We have
compared the performance of EUCAST and CLSI clinical
breakpoints, the additional CLSI recommendations for identi-
fication of carbapenemase producers and the EUCAST EC-
OFFs in the detection of KPC-producing and VIM-producing
K. pneumoniae.
The present EUCAST, but not CLSI, clinical MIC break-
point for ertapenem detected all KPC and VIM producers.
For meropenem, a substantial number of strains had MIC
values below both the CLSI and EUCAST clinical break-
points. The EUCAST ECOFF for meropenem and ertapenem
identified all carbapenemase producers. With imipenem, sev-
eral failures were observed, both with the ECOFF and the
clinical breakpoints. The recommended MIC cut-off for
screening recommended by the CLSI is identical to the clini-
cal EUCAST breakpoints for imipenem and meropenem,
whereas the recommended ertapenem cut-off is two dilution
steps higher than the corresponding EUCAST clinical break-
point, and hence performed less well in identifying all carba-
penemase producers.
With EUCAST disk diffusion breakpoints, all carbapenem-
ase producers were discovered with meropenem and ertape-
nem, whereas four strains were categorized as susceptible to
imipenem. The CLSI recommendation for disk diffusion
identified all carbapenemase producers with the carbapenem
cut-off values <22 mm. With CLSI clinical breakpoints, 18
isolates were categorized as susceptible to imipenem, 14 to
meropenem and three to ertapenem. For all three carbapen-
ems, the maximum zone diameter was 21 mm. Meropenem
TABLE 2. MIC (Etest), disk diffusion zone diameters and VITEK2 results for VIM-producing Klebsiella pneumoniae
Isolate
MIC (mg/L)
Zone
diameters (mm)
VITEK2 MIC correlates (mg/L) and advanced expert system interpretation with various cards
N25 N27 N29 N106 N107
IPM MEM ERT IPM MEM ERT IPM MEM ERT Carb IPM Carb MEM Carb ERT Carb IPM MEM ERT Carb
6 ‡32 ‡32 ‡32 8 6 6 ‡16 ‡16 ‡8 Yes ‡16 Yes ‡16 Yes ‡8 Yes ‡16 ‡16 ‡8 Yes
194 ‡32 ‡32 ‡32 6 6 8 ‡16 ‡16 ‡8 Yes ‡16 Yes ‡16 Yes ‡8 Yes ‡16 ‡16 ‡8 Yes
213 ‡32 ‡32 ‡32 6 6 6 ‡16 ‡16 ‡8 Yes ‡16 Yes ‡16 Yes ‡8 Yes 8 ‡16 ‡8 Yes
220 ‡32 ‡32 ‡32 8 6 8 ‡16 ‡16 ‡8 Yes ‡16 Yes ‡16 Yes ‡8 Yes ‡16 ‡16 ‡8 Yes
229 ‡32 ‡32 2 21 20 21 8 1 4 Yes 4 Yes 1 Yes 4 Yes 4 1 4 Yes
309 16 4 2 21 21 19 4 1 1 Yes 2 Yes 1 Yes 4 Yes 4 1 4 Yes
374 ‡32 ‡32 2 14 13 16 ‡16 8 ‡8 Yes ‡16 Yes 8 Yes ‡8 Yes ‡16 8 ‡8 Yes
389 ‡32 ‡32 16 6 6 10 8 ‡16 ‡8 Yes 8 Yes ‡16 Yes ‡8 Yes 8 ‡16 ‡8 Yes
430 ‡32 ‡32 16 6 6 13 ‡16 ‡16 ‡8 Yes ‡16 Yes ‡16 Yes ‡8 Yes ‡16 ‡16 ‡8 Yes
440 ‡32 2 2 20 21 20 4 1 £0.5 No 4 Yes 1 Yes 4 Yes 8 1 4 Yes
754 ‡32 ‡32 ‡32 6 6 6 ‡16 ‡16 ‡8 Yes ‡16 Yes ‡16 Yes ‡8 Yes ‡16 ‡16 ‡8 Yes
842 ‡32 ‡32 ‡32 6 6 6 ‡16 ‡16 ‡8 Yes ‡16 Yes ‡16 Yes ‡8 Yes ‡16 ‡16 ‡8 Yes
T14789 ‡32 ‡32 ‡32 6 6 6 ‡16 ‡16 ‡8 Yes ‡16 Yes ‡16 Yes ‡8 Yes ‡16 ‡16 ‡8 Yes
O¨N2211 ‡32 ‡32 4 14 17 17 ‡16 8 ‡8 Yes ‡16 Yes 8 Yes ‡8 Yes ‡16 8 ‡8 Yes
HV1491 ‡32 ‡32 ‡32 12 6 6 ‡16 ‡16 ‡8 Yes ‡16 Yes ‡16 Yes ‡8 Yes ‡16 ‡16 ‡8 Yes
U60687 ‡32 ‡32 ‡32 11 10 6 8 ‡16 ‡8 Yes 8 Yes ‡16 Yes ‡8 Yes 8 ‡16 ‡8 Yes
AO15200 ‡32 16 ‡32 14 13 15 ‡16 2 4 Yes 8 Yes 2 Yes 4 Yes ‡16 2 4 Yes
B22365 ‡32 ‡32 ‡32 10 9 9 4 1 ‡8 Yes 4 Yes 1 Yes ‡8 Yes 8 1 ‡8 Yes
K45-67 4 2 1 15 13 17 4 1 £0.5 Yes 4 Yes 1 Yes ‡8 Yes 8 1 £0.5 Yes
K46-62 ‡32 32 16 12 14 15 4 1 £0.5 No 4 Yes 1 Yes £0.5 No 4 1 £0.5 Yes
IPM, imipenem; MEM, meropenem; ERT, ertapenem; Carb, interpreted as a carbapenamase producer by the advanced expert system.
Bold face denotes erroneous interpretation by the VITEK2 advanced expert system.
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and ertapenem performed better in the separation of KPC/
VIM producers and wild-type strains than imipenem. Disk dif-
fusion seems to be a particularly useful tool in screening for
KPC-producing and VIM-producing K. pneumoniae; in fact,
the disk diffusion breakpoints identified a much higher pro-
portion of the carbapenemase producers than the MIC
breakpoints. Current EUCAST breakpoints were useful for
the detection of KPC and VIM producers, except in a few
cases for meropenem and in several cases for imipenem.
Pasteran et al. [17] reported that for detection of class A
carbapenemases, the use of an imipenem breakpoint of
‡1 mg/L was superior to screening with meropenem or
ertapenem. In contrast, this breakpoint failed to identify
several of the carbapenemase producers in this study,
mainly because our strain collection included a number of
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FIG. 1. Zone diameter distributions with EUCAST epidemiological
cut-offs (ECOFFs) (wild type (WT)), CLSI clinical breakpoints and
EUCAST clinical breakpoints indicated as vertical lines: (a) zone
diameter distribution for imipenem; (b) zone diameter distribution
for meropenem; and (c) zone diameter distribution for ertapenem.
R, resistant; S, susceptible.
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FIG. 2. MIC distributions with EUCAST epidemiological cut-offs
(ECOFFs) (wild type (WT)), CLSI clinical breakpoints and EUCAST
clinical breakpoints indicated as vertical lines: (a) MIC distribution
for imipenem; (b) MIC distribution for meropenem; and (c) MIC
distribution for ertapenem. R, resistant; S, susceptible.
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metallo-b-lactamase-producing K. pneumoniae strains. Also,
the reason why meropenem and ertapenem performed less
well in the study by Pasteran et al. [17] was the inclusion of
isolates with class A carbapenemases that, to a lesser degree,
affect meropenem and ertapenem, such as Sme. As class A
carbapenemases other than KPC constitute a more limited
clinical problem at present, it is more important to accu-
rately detect all metallo-b-lactamase-producing Enterobacteria-
ceae. Still, this is an important reminder that appropriate
detection of carbapenemase producers of all molecular
classes can best be achieved by testing all of the above-
mentioned carbapenems.
We observed that the clinical EUCAST breakpoint for
ertapenem had the highest sensitivity in detection of carba-
penemase producers. Recent studies have shown that the
positive predictive value of ertapenem resistance for
carbapenemase production is high in settings with a high
prevalence of carbapenemase production among carbape-
nem-non-susceptible strains [18,19]. Hence, ertapenem could
be a good screening substrate in populations with a high
prevalence of carbapenemases [19]. However, mechanisms
reducing carbapenem susceptibility other than carbapenem-
ase production in Enterobacteriaceae are more common in
many regions of the world, challenging the usefulness of
ertapenem as a screening substrate for carbapenemase pro-
duction [20]. Therefore, the meropenem ECOFF may be a
better alternative for screening, at least in a setting with low
carbapenemase production. Probably, it will also be an
advantage to increase the screening cut-off for meropenem
from the ECOFF to 0.5 mg/L, as the latter cut-off was able
to detect all carbapenemase producers in this study, and also
probably gives better specificity than the ECOFF at
0.125 mg/L.
Our results support the notion that the use of antibiotic
cards in VITEK2 containing imipenem as the only carbapenem
(AST N027) increases the risk of major failures in the detec-
tion of carbapenemase production in K. pneumoniae. In con-
trast, the card with meropenem as the only carbapenem
(AST N029) had no failures. VITEK2 seems to be a useful
tool for the detection of carbapenemases in K. pneumoniae,
with the exception of using imipenem as the only carbapenem
(AST N027). However, the verdict of the expert system
should be compared with the carbapenem MIC correlates,
and if one or several of these are above the lower detection
limit in the cards, one should exclude carbapenemase produc-
tion by appropriate phenotypic and/or genotypic methods.
ESBL detection was conducted with three methods: Etest,
CDT and VITEK2. The ESBL Etest was negative in all strains.
Up to 40% of the strains became ESBL-positive with CDT.
With VITEK2, depending on the card, up to 13% of the
strains were ESBL-positive. Hence, interpretation of positive
ESBL test results must be assessed in relation to carbapenem
susceptibility profiles. If carbapenem MICs are above the EC-
OFFs, it is important to continue testing for carbapenemase
production.
Recently, the CLSI decided to lower the carbapenem MIC
breakpoints, a change that has not yet been implemented
(R. Canton, personal communication). One of the arguments
was that lowering the meropenem-susceptible and imipe-
nem-susceptible breakpoints to £1 mg/L and the ertapenem-
susceptible breakpoint to £0.25 mg/L would improve the
detection of carbapenemase producers. However, our data
indicate that a decrease in the meropenem-susceptible and
imipenem-susceptible breakpoints would still not produce
adequate capture of carbapenemase producers. Another
argument presented has been that there is a risk of failure
when KPC producing K. pneumoniae strains are treated with
carbapenems. A study by Weisenberg et al. [21] investigated
clinical outcomes in 11 patients infected with K. pneumoniae
strains with MIC correlates of £4 mg/L according to VITEK2.
Among these patients, 8/11 received imipenem, and half of
them experienced treatment failure. According to the Etest,
the imipenem MICs for the four patients were 2, 8, 12 and
‡32 mg/L. Hence, only one of the failures featured an isolate
that was susceptible according to EUCAST breakpoints. It
should also be noted that among the isolates reported in this
study, only two would have tested susceptible in VITEK2
with EUCAST breakpoints. Only one of the patients infected
with strains with MICs £2 mg/L was treated with imipenem,
and in this case microbiological and clinical success was
observed. Hence, there are, at present, no data supporting
the idea that treatment of KPC-producing K. pneumoniae
with carbapenems will lead to clinical failure when the MICs
are £2 mg/L.
The EUCAST clinical susceptible breakpoints for imipenem
and meropenem (£2 mg/L) are supported by pharmacody-
namic data (http://www.eucast.org/documents/rd/; last
accessed 25 March 2010), and, moreover, a study by Daikos
et al. [22] showed no evidence of poorer outcomes in
patients treated with carbapenems for infections caused by
carbapenemase producers with MICs £4 mg/L. In this study,
26 of the patients who were infected with VIM-producing
K. pneumoniae strains with MICs in the susceptible range for
imipenem and/or meropenem were treated with carbapen-
ems, either as monotherapy or as combination therapy. Only
four of these patients experienced clinical failure (G. Daikos,
personal communication). This observation could be in
support of avoiding lowering of the clinical breakpoints in a
setting where few treatment options exist. With the use
of epidemiological cut-offs as screening tools, the need for
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lowering of breakpoints for epidemiological purposes is
minimal. However, more studies are clearly needed to
document the safety of carbapenems in infections caused by
carbapenemase-producing Enterobacteriaceae with low carba-
penem MICs, and the susceptible breakpoints should be
re-evaluated if evidence suggests a poorer outcome when
the MIC is £2 mg/L.
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